🏆 Humbled to receive the Best Poster Prize at #EAU25! 🎉 Our study challenges the idea that more biopsy = better outcomes in focal therapy. Findings suggest MRI visibility—not biopsy density—drives recurrence risk. #ProstateCancer #FocalTherapy #Urology #CancerResearch @

🚀 Does More Biopsy = Better Outcomes in Focal Therapy? 🔍 Our #EAU25 study challenges the assumption that higher biopsy sampling density improves recurrence prediction. Findings suggest MRI visibility—not biopsy density—drives patient selection & outcomes.

An incredible session on AI from treatment and beyond of prostate cancer by @Cacciamani_MD with very informative talks @MountsinaiUro @michael_gorin @girish_nadkarni @prokarurol @AshTewariMD

🎉Congratulations to the #IP6CHAIROS study team for successfully completing recruitment of over 6️⃣0️⃣0️⃣ patients! @IP_London @NIHRCRNWessex @uclh @nhsuhcw @ChelwestFT @WestMidHospital Let’s keep the momentum going until completion! 💪🏻💯

Looking forwards to ⁦@AbhinavSidana⁩ ⁦@EmbertonMark⁩ ⁦@FocalSociety⁩ ⁦@SonablateCorp⁩ ⁦@angiodynamics⁩ #focal-therapy #HIFU #Cryoablation #nanoknife ⁦@DrGaganGautam⁩ ⁦@VattikutiRobotx⁩ @roboticsurgery

Attended a fantastic CME on NanoKnife by ⁦@AquilantOncol⁩. It was an incredible opportunity to learn from and interact with world leaders in the field. @therap_focal @FocalSociety @UKFocal @gland_ambition @EmbertonMark @AbhinavSidana @arvinkgeorge @usioffice

BAUS @ Birmingham. Making new connections. Revisiting old ones. Knowledge exchange ! ⁦@IBUSurology⁩ ⁦@EmbertonMark⁩ @PeaPeaspot⁩ ⁦@joeurol⁩ ⁦@usioffice⁩ ⁦@VattikutiRobotx⁩ ⁦@YouthUSI⁩ ⁦@mrsprostate⁩ ⁦@stingrai78⁩ ⁦⁦

Nice work @AquaAsif @PrimeMRI

Intermediate-risk disease who elected primary PGCA, the five-year freedom-from-failure rate was 91 percent. This includes near- and in-field recurrences 2/3 with int-risk CaP would opt for CRYO over radical surgery.🚨 This is huge 👍🏻☑️ @ibus @usioffice @usiboe @DrRavimohanSM

Things taught at the @AmerUrological #AUA2024 1- focal therapy is not about pushing a button! 2- Understand the biology of cancer 3- Imaging, Patient Selection and Follow up matter! September 19-22 2024 @Endo_Society @SocietySURS https://t.co/vCYX8yfRF4

🎯Is Focal Therapy ready for prime time?!? 🕰️ There is still time to join the great debate @IauaSociety 🤺The duel with @AdityaBagrodia starts at 9:30am 🏠 ROOM 205 #AUA24 @AmerUrological @gpalapa2 @AbhinavSidana

Prostate calcifications are deterrents for post gland treatment modalities like #HIFU paving the way for more effective anterior gland treatment modalities of #cryotherapy and #Nanoknife ⁦⁦@FocalSociety⁩ ⁦@therapy_focal⁩ ⁦@UkFocal⁩ ⁦@AbhinavSidana⁩

🚨 Breaking results 🚨 @PrimeMRI study presented at #EAU24 @Uroweb. This 🌍 multicentre trial (n=555, 22 sites) showed that biparametric MRI without contrast is non-inferior 2 multiparametric MRI & should be the new standard for prostate cancer diagnosis if image quality is good

Do we still need contrast in our MRIs for Prostate Diagnostics ?! Eagerly waiting for answers and looking forward to it. @veerukasi @mrsprostate

@TimesAlgebraIND The proudest moment for a 💕mother is when her son comes in front of her wearing army dress 🙏 Jai Hind

Despite losing the first Test, #TeamIndia bounced back impressively to clinch the series with a comfortable 4-1 scoreline. Throughout the series, the team has capitalised on every opportunity presented to them. @imkuldeep18 and @ashwinravi99's outstanding performances were

'Focussed' progression is the key. 'Target' being the prostate! Skill upgradation. Guided by world leaders. @uclh @mrsprostate @gland_ambition @veerukasi @ClementOrczyk @alistergrey @EmbertonMark

https://t.co/Pi9BRLRoml

⛳️ To finish off 🙌🏼 the #PRIME milestones, we are proud to announce the fantastic recruitment of our UK sites 🇬🇧 throughout the past year and a bit! 🚀✨ 🌟 @CamUrology: 3️⃣5️⃣➕ 🌟 @uclh: 2️⃣5️⃣➕ 🌟 @RoyalFreeNHS: 5️⃣➕ #UroSoMe #prostatecancer #prostateMRI

This is an interesting Would be interesting to read through the paper